8-K ·Filed May 13, 2026

LGVN

Longeveron Inc.
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago SEC0001213900-26-055806
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Monitor August 2026 ELPIS II readout as the primary catalyst; cash runway into Q4 2026 provides some buffer but additional financing will be needed. The private placement was dilutive (shares outstanding increased from 21.4M to 29.3M), but necessary for operations.

DirectionNeutral
Confidencehigh
Horizonmonths
Final — all horizons settled through T+60d
LGVN ▲ +4.74% at T+60d
NEUTRAL call ✓ call won +4.74% · α vs SPY +1.15% · entry $0.7030 → $0.7363
Entry anchored
May 13, 2026
via day open
T+1d
-4.55%
call -4.55% · α -3.32%
$0.6710
settled 5mo ago
T+5d
+2.56%
call +2.56% · α +3.28%
$0.7210
settled 5mo ago
T+20d
+11.38%
call +11.38% · α +12.24%
$0.7830
settled 4mo ago
T+60d
+4.74%
call +4.74% · α +1.15%
$0.7363
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Longeveron reported Q1 2026 results in line with consensus: EPS -$0.19 matched Street estimates and revenue of $398K was essentially flat YoY. The key positive was a strengthened cash position of $15.8M following a $15M private placement, extending runway into Q4 2026. The primary catalyst remains top-line data from the ELPIS II Phase 2b HLHS trial expected in August 2026.

Key Financial Metrics

EPS
$-0.19
est $-0.19 · 0.0%
Revenue
$398.0K
+4.5% YoY
Rating
in line
Gross Margin
0.663%

Key Facts

  • Q1 2026 EPS -$0.19 (in line with consensus of -$0.19)
  • Q1 2026 revenue $398K vs $381K in Q1 2025 (flat)
  • Cash and equivalents $15.8M as of March 31, 2026 vs $4.7M at year-end 2025
  • Closed $15M private placement (up to $30M) led by Coastlands Capital
  • Cash runway extended into Q4 2026
  • ELPIS II Phase 2b HLHS top-line results anticipated in August 2026

Financial Impact

No material financial impact from earnings; cash position improved by ~$11M from prior quarter

cashepsdilution

Risk Factors

  • Dilution from PIPE and potential future offerings
  • Single point of failure on ELPIS II trial results
  • Need for additional capital before Q4 2026
  • Pre-revenue stage with ongoing operating losses

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-055806
Document: ea0290436-8k_longeveron.htm0001213900-26-055806
Document: 0001213900-26-055806-index-headers.html0001213900-26-055806
Document: 0001213900-26-055806-index.html0001213900-26-055806
Document: 0001213900-26-055806.txt0001213900-26-055806
8-K Data (Synthetic)0001213900-26-055806
12 reports for LGVN
Performance horizon
83% Hit rate 5 of 6 directional calls best @ T+60▲ +42.59%Apr 10, 2026
Filters
Rows
Reports for LGVN — sortable, filterable
TypeNow
Sep 14, 2026
17d ago
8-K
BULLISH ★ 5/10
$6.86 $2.49▼ −63.70%▼ −64.52%$2.57 (−62.61%)
Jul 13, 2026
11w ago
3
NEUTRAL ★ 2/10
$0.6223 $0.6022▼ −3.23%▼ −1.93%$2.57 (+312.18%)
Jun 5, 2026
16w ago
8-K
NEUTRAL ★ 4/10
$0.7540 $0.7900▲ +4.77%▲ +2.66%$2.57 (+240.19%)
May 20, 2026
19w ago
Press Release
NEUTRAL ★ 4/10
$0.7210 $0.8150▲ +13.04%▲ +11.44%$2.57 (+255.76%)
May 13, 2026
20w ago
8-K
NEUTRAL ★ 3/10
$0.7030 $0.7210▲ +2.56%▲ +3.28%$2.57 (+264.86%)
May 8, 2026
20w ago
8-K
BEARISH ★ 7/10
$0.8380 $0.6760▲ +19.33%▲ +19.25%$2.57 (−206.09%)
Apr 20, 2026
23w ago
EFFECT
BEARISH ★ 6/10
$1.04 $0.9000▲ +13.46%▲ +14.37%$2.57 (−146.63%)
Apr 10, 2026
24w ago
8-K
NEUTRAL ★ 3/10
$1.12 $1.04▼ −7.14%▼ −10.44%$2.57 (+129.02%)
Apr 10, 2026
24w ago
S-1
BEARISH ★ 6/10
$1.12 $1.04▲ +7.14%▲ +10.44%$2.57 (−129.02%)
Mar 17, 2026
28w ago
Press Release
BEARISH ★ 7/10
$0.9760 $0.9730▲ +0.31%▼ −0.41%$2.57 (−162.81%)
Showing 10 of 12

US Market Status

Market Open — Closes in 32m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access